Tenofovir alafenamide

From Wikipedia, the free encyclopedia
  (Redirected from Tenofovir alafenamide fumarate)
Jump to: navigation, search
Tenofovir alafenamide
Tenofovir alafenamide structure.svg
Systematic (IUPAC) name
Isopropyl (2S)-2-[[[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]propanoate
Clinical data
Trade names Genvoya (with elvitegravir, cobicistat and emtricitabine)
Odefsey (with emtricitabine and rilpivirine)
Descovy (with emtricitabine)
Routes of
administration
Oral (tablets)
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Protein binding ~80%[1]
Biological half-life 0.51 hours
Excretion Feces (31.7%), urine (<1%)
Identifiers
CAS Number 379270-37-8
ATC code J05AR17 (WHO) J05AR18 (WHO) J05AR19 (WHO) (combination codes)
PubChem CID 9574768
DrugBank DB09299
ChemSpider 7849225
UNII EL9943AG5J YesY
KEGG D10428
ChEBI CHEBI:90926 YesY
ChEMBL CHEMBL2107825
Chemical data
Formula C21H29N6O5P
Molar mass 476.466 g/mol
Tenofovir alafenamide fumarate, the salt used in drug formulations.

Tenofovir alafenamide (INN/USAN, formerly GS-7340) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent.[2][3]

Gilead announced a phase 3 clinical trial evaluating a single-tablet regimen combining tenofovir alafenamide with cobicistat, emtricitabine and elvitegravir[4] and developed a coformulation of the drug with cobicistat, emtricitabine and the protease inhibitor darunavir.[5][6][7] In a 48 week study comparing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (trade name Genvoya), the results showed the newer drug to be noninferior to the established agent, but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function.[8][9][10] The FDA approved the TAF-based treatment regimen for treatment of HIV-1 in November 2015.[11] Genvoya is the first TAF-based regimen to receive approval.[11]

Fixed-dose combinations containing tenofovir alafenamide[edit]

See also[edit]

References[edit]

  1. ^ "GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) Tablets, for Oral Use. Full Prescribing Information" (PDF). Gilead Sciences, Inc. Foster City, CA 94404. 
  2. ^ Eisenberg, E. J.; He, G. X.; Lee, W. A. (2001). "Metabolism of Gs-7340, A Novel Phenyl Monophosphoramidate Intracellular Prodrug of Pmpa, in Blood". Nucleosides, Nucleotides and Nucleic Acids. 20 (4–7): 1091–1098. doi:10.1081/NCN-100002496. PMID 11562963. 
  3. ^ M Markowitz, A Zolopa, et al. GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir Disoproxil Fumarate During 14 Days of Monotherapy in HIV-1 Infected Subjects. 18th Conference on Retroviruses and Opportunistic Infections 2 Mar 2011. Paper # 152LB
  4. ^ "Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide" (Press release). Gilead. January 2013. 
  5. ^ McQueen, Courtney (16 Nov 2011). "Gilead And Tibotec To Develop Single-Pill Protease Inhibitor-Based Combination Regimen". The AIDS Beacon. 
  6. ^ GS-7340 Packs Greater HIV Punch, Potentially Better Safety, Versus Viread Horn, Tim. 15 Mar 2012. AIDSmeds.com
  7. ^ Pharmacokinetics of a Novel EVG/COBI/FTC/GS-7340 Single Tablet Regimen. 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain. April 16–18, 2012.
  8. ^ Once-Daily Tenofovir Prodrug Combo Pill as Effective as Stribild. AIDSmeds.com 1 Nov 2012.
  9. ^ CROI 2013: New Pro-drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated. Highleyman, Liz. HIVandHepatitis.com. 6 March 2013.
  10. ^ Horn, T. et al. Tenefovir Alafenamide Fumarate (TAF) Sign-On Letter to Gilead. 13 June 2013. Treatment Action Group.
  11. ^ a b "U.S. Food and Drug Administration Approves Gilead's Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection". Gilead. 5 November 2015. 
  12. ^ "Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide) Tablets, for Oral Use. U.S. Full Prescribing Information" (PDF). Gilead Sciences, Inc. Retrieved 2 March 2016. 
  13. ^ "Descovy (emtricitabine and tenofovir alafenamide) Tablets, for Oral Use. U.S. Full Prescribing Information" (PDF). Gilead Sciences, Inc. Retrieved 5 April 2016. 
  14. ^ "Comparison of tenofovir prodrugs: TAF vs TDF". DRUG R&D INSIGHT. Retrieved 24 November 2015. 
  15. ^ Murakami, E.; Tolstykh, T.; Bao, H.; Niu, C.; Steuer, H. M. M.; Bao, D.; Chang, W.; Espiritu, C.; Bansal, S.; Lam, A. M.; Otto, M. J.; Sofia, M. J.; Furman, P. A. (26 August 2010). "Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977". Journal of Biological Chemistry. 285 (45): 34337–34347. doi:10.1074/jbc.M110.161802.